Floatz logo

Carboplatin

BRCA Mutation

Okayama UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the BRCA Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
Okayama University
Phase 3B
Cyclophosphamide
Okayama University
Phase 2CCC
Tranexamic Acid
Northwestern University
Phase 2CCC
TAMOXIFEN
European Institute of Oncology
Phase 2CCC
Pembrolizumab
Okayama University
Phase 2CCC

View all 12 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →